Gemini Therapeutics (NASDAQ:GMTX) Trading Up 0.6% - What's Next?

Key Points

• Gemini Therapeutics (NASDAQ:GMTX) shares increased by 0.6% during trading on Wednesday, closing at $59.79 with a market cap of $2.59 billion.
• The stock's price-to-earnings ratio is -59.79, indicating that the company is not currently profitable, while its 200-day moving average stands at $51.74.
• Gemini Therapeutics is a clinical stage precision medicine company focused on developing therapies for age-related macular degeneration (AMD), with its lead candidate being GEM103.

Gemini Therapeutics, Inc. (NASDAQ:GMTX - ) shares were up 0.6% during trading on Wednesday . The company traded as high as $60.28 and last traded at $59.79. Approximately 227,981 shares were traded during trading, an increase of 20% from the average daily volume of 189,291 shares. The stock had previously closed at $59.41.

Gemini Therapeutics Trading Up 0.6%

The business's fifty day simple moving average is $57.21 and its 200 day simple moving average is $51.74. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -59.79 and a beta of -0.12.

Gemini Therapeutics Company Profile

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.